Syed Husain, MD
Infectious Disease · Sterling Heights, MINPI 1861408734
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $220 and has fallen 76.8% since, to $51 in 2025.
Across 16 payments — averaging $44.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$136
- Insmed, Inc.$132
- Nestle Healthcare Nutrition Inc.$103
- Tetraphase Pharmaceuticals, Inc.$88
- AbbVie$56
- Johnson & Johnson$50
- plus $143 from 4 others
Across 167 payments — averaging $2366.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$392K
- Bristol Myers Squibb$3K
What the payments were for
- Food & beverage$708100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 2 | $136 |
| Insmed, Inc. | 1 | $132 |
| Nestle Healthcare Nutrition Inc. | 1 | $103 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $88 |
| AbbVie | 2 | $56 |
| Johnson & Johnson | 2 | $50 |
| Amgen | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Pfizer | 1 | $25 |
| AstraZeneca | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$708 in reported general payments places this provider in the 70th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsentressRaltegravir Potassium | 11 | $21,525 |
| Daptomycin | 27 | $12,630 |
| ErtapenemErtapenem Sodium | 29 | $12,232 |
| Cefepime Hcl | 23 | $2,872 |
| Vancomycin Hcl | 32 | $1,328 |
| MethotrexateMethotrexate Sodium | 31 | $1,119 |
| Prednisone | 40 | $512 |
| CeftriaxoneCeftriaxone Sodium | 22 | $310 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Sterling Heights
- Vicente RedondoSterling Heights$1K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Keith KayeAnn Arbor$187K
- Rodger MacarthurDetroit$150K
- Chris FarnumLansing$102K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Christopher CarpenterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.